CVS HEALTH (AND SUBSIDIARIES) for CVS HEALTH (AND SUBSIDIARIES)
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Veterans VET
Issues related to veterans access to healthcare and VA CHOICE Act reauthorization. S. 1526, The Veterans Access to Community Care Act of 2017 H.R. 4242, The VA Care in the Community Act S. 2184, The Veterans Community Care and Access Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHANNON PENBERTHY | — |
Labor Issues/Antitrust/Workplace LBR
Issues related to CVS Health announced merger with Aetna.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| TEGAN GELFAND | — |
| ASHLI PALMER | — |
| SHANNON PENBERTHY | — |
| AMY ROSENBAUM New | Sr Advisor/Deputy Advisor to the President; Policy Director, Office of Speaker/Minority Leader; Sr Advisor, Committee on Education & the Workforce; Research Dir, Asst to Minority Leader; Staff Asst, Leg Asst, Leg Dir, Policy Dir, Congressman Meehan |
| MELISSA SCHULMAN | — |
Taxation/Internal Revenue Code TAX
Issues related to health savings accounts, the health insurance tax and other taxes included in the Affordable Care Act. S. 1859, the Healthcare Tax Relief Act of 2017 H.R. 95, Making Further Continuing Appropriations for the fiscal year ending September 30, 2018 H.R. 4620, the Protecting Families and Small Business Act of 2018 H.R. 5138, the Bipartisan HSA Improvement Act of 2018
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| TEGAN GELFAND | — |
| SHANNON PENBERTHY | — |
Health Issues HCR
Issues related to implementation and changes to the Affordable Care Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| TEGAN GELFAND | — |
| ASHLI PALMER | — |
| SHANNON PENBERTHY | — |
| AMY ROSENBAUM New | Sr Advisor/Deputy Advisor to the President; Policy Director, Office of Speaker/Minority Leader; Sr Advisor, Committee on Education & the Workforce; Research Dir, Asst to Minority Leader; Staff Asst, Leg Asst, Leg Dir, Policy Dir, Congressman Meehan |
Copyright/Patent/Trademark CPT
Issues related to barriers to generic drug and biosimilar market entry including pay-for-delay and REMS. S. 124, The Preserve Access to Affordable Generics Act of 2017 S.771/H.R. 1776, The Improving Access to Affordable Prescription Drugs Act of 2017 H.R. 2051, The Fair Access for Safe and Timely Generics Act of 2017 S. 974/H.R. 2212, The Creating and Restoring Equal Access to Equivalent Samples Act of 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| TEGAN GELFAND | — |
| ASHLI PALMER | — |
| SHANNON PENBERTHY | — |
| AMY ROSENBAUM New | Sr Advisor/Deputy Advisor to the President; Policy Director, Office of Speaker/Minority Leader; Sr Advisor, Committee on Education & the Workforce; Research Dir, Asst to Minority Leader; Staff Asst, Leg Asst, Leg Dir, Policy Dir, Congressman Meehan |
| MELISSA SCHULMAN | — |
Medicare/Medicaid MMM
Issues related to prescription drug abuse, Medicare Part D, and Medicare payment for home infusion. S.413/H.R. 1039, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2017 H.R.1316, The Prescription Drug Price Transparency Act of 2017 S. 2460/H.R. 3528, The Every Prescription Conveyed Safely Act of 2017 S. 1738/H.R. 3163, The Medicare Home Infusion Therapy Act of 2017 H.R. 3178, The Medicare Part B Improvement Act of 2017 S. 2553, The Know the Lowest Price Act of 2018 H.R. 4841, The Standardizing Electronic Prior Authorization for Safe Prescribing Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| TEGAN GELFAND | — |
| ASHLI PALMER | — |
| SHANNON PENBERTHY | — |
| AMY ROSENBAUM New | Sr Advisor/Deputy Advisor to the President; Policy Director, Office of Speaker/Minority Leader; Sr Advisor, Committee on Education & the Workforce; Research Dir, Asst to Minority Leader; Staff Asst, Leg Asst, Leg Dir, Policy Dir, Congressman Meehan |
Pharmacy PHA
Issues related to prescription drug abuse, medication adherence, generic drug approvals, biologic exclusivity periods, drug price transparency, and gag clauses. H.R.1316, The Prescription Drug Price Transparency Act of 2017 S. 778/H.R. 1854, The Prescription Drug Monitoring Act of 2017 S. 2460/H.R. 3528, The Every Prescription Conveyed Safely Act of 2017 S.892/H.R. 4408, The Opioid Addiction Prevention Act of 2017 S. 2456 / H.R. 5311, The CARA 2.0 Act of 2018 H.R. 4482, The Opioid Abuse Deterrence, Research, and Recovery Act of 2017 S. 2553, The Know the Lowest Price Act of 2018 S. 2554, The Patient Right to Know Drug Prices Act of 2018 H.R. 5343, The Prescription Transparency Act of 2018
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| TEGAN GELFAND | — |
| ASHLI PALMER | — |
| SHANNON PENBERTHY | — |
| AMY ROSENBAUM New | Sr Advisor/Deputy Advisor to the President; Policy Director, Office of Speaker/Minority Leader; Sr Advisor, Committee on Education & the Workforce; Research Dir, Asst to Minority Leader; Staff Asst, Leg Asst, Leg Dir, Policy Dir, Congressman Meehan |
| MELISSA SCHULMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.